Latest Period
Q1 2026
Security Snapshot
ANI PHARMACEUTICALS INC - Common Stock (ANIP) Institutional Ownership
CUSIP: 00182C103
13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026
Institutions Reporting
275
Shares (Excl. Options)
23,285,859
Price
$76.90
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock
- Symbol
- ANIP on Nasdaq
- Shares outstanding
- 22,278,088
- Price per share
- $80.14
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 23,285,859
- Total reported value
- $1,790,008,319
- % of total 13F portfolios
- 0%
- Share change
- +1,806,100
- Value change
- +$137,327,183
- Number of holders
- 275
- Price from insider filings
- $80.14
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- ANIP - ANI PHARMACEUTICALS INC - Common Stock is tracked under CUSIP 00182C103.
- 275 institutions reported positions in Q1 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 284 to 275 between Q4 2025 and Q1 2026.
- Reported value moved from $1,669,959,225 to $1,790,008,319.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 275 institutions filings for Q1 2026.
Security key
00182C103
Latest holder period
Q1 2026
13F holders
275
13D/G owners
4
CIK / CUSIP context first
Open Q1 2026 holders
ANIP full holder history
ANI PHARMACEUTICALS INC SEC filings
ANI PHARMACEUTICALS INC company facts
ANI PHARMACEUTICALS INC insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 00182C103:
Significant Owners of ANI PHARMACEUTICALS INC - Common Stock (ANIP) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 11% | $230,596,038 | 2,517,424 | BlackRock, Inc. | 30 Sep 2025 | |||
| Meridian Venture Partners II GP, L.P. | 4.8% | -12% | $66,419,394 | -$9,630,000 | 1,034,570 | -13% | Robert E. Brown, Jr. | 21 Aug 2025 |
| MILLENNIUM MANAGEMENT LLC | 3.8% | -28% | $57,136,569 | -$19,037,261 | 818,341 | -25% | Millennium Management LLC | 31 Mar 2025 |
| INTEGRATED CORE STRATEGIES (US) LLC | 0.3% | -98% | $5,976,442 | -$96,309,614 | 65,245 | -94% | Millennium Management LLC | 30 Sep 2025 |
As of 31 Mar 2026, 275 institutional investors reported holding 23,285,859 shares of ANI PHARMACEUTICALS INC - Common Stock (ANIP). This represents 105% of the company’s total 22,278,088 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of ANI PHARMACEUTICALS INC - Common Stock (ANIP) together control 63% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 12% | 2,747,492 | +3.2% | 0% | $211,282,135 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.7% | 823,064 | 0% | 0% | $63,293,622 |
| Soleus Capital Management, L.P. | 3.7% | 820,243 | +69% | 2.6% | $63,076,687 |
| STATE STREET CORP | 3.5% | 771,587 | +6.1% | 0% | $59,335,040 |
| TANG CAPITAL MANAGEMENT LLC | 3.2% | 707,500 | +47% | 2.8% | $54,406,750 |
| GOLDENTREE ASSET MANAGEMENT LP | 3% | 667,981 | 3% | $51,295,618 | |
| Deep Track Capital, LP | 2.7% | 600,000 | +26% | 0.95% | $46,140,000 |
| MILLENNIUM MANAGEMENT LLC | 2.7% | 592,013 | +9.7% | 0.03% | $45,525,800 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 2.5% | 564,360 | +19% | 0.02% | $43,399,284 |
| DIMENSIONAL FUND ADVISORS LP | 2.4% | 531,190 | +8.9% | 0.01% | $40,842,741 |
| UBS Group AG | 2.2% | 497,702 | +230% | 0.01% | $38,273,284 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.2% | 489,201 | +2.5% | 0% | $37,626,432 |
| Nuveen, LLC | 1.8% | 402,357 | +3.9% | 0.01% | $30,941,253 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.7% | 375,965 | 0% | 0% | $28,911,709 |
| Global Alpha Capital Management Ltd. | 1.6% | 361,240 | -39% | 1.7% | $27,779,356 |
| Ranger Investment Management, L.P. | 1.6% | 360,083 | -0.63% | 2% | $27,690,383 |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 1.5% | 327,276 | +3.3% | 0.08% | $25,167,524 |
| Invesco Ltd. | 1.5% | 324,349 | +71% | 0% | $24,942,437 |
| DEUTSCHE BANK AG\ | 1.4% | 319,675 | -19% | 0.01% | $24,583,008 |
| Jones Hill Capital LP | 1.4% | 318,591 | 0% | 5.3% | $24,499,648 |
| KENNEDY CAPITAL MANAGEMENT LLC | 1.3% | 293,996 | +38% | 0.48% | $22,608,292 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 1.3% | 287,563 | -3.9% | 0.04% | $22,114,000 |
| Parkman Healthcare Partners LLC | 1.3% | 280,575 | +94% | 2.2% | $21,576,218 |
| AMERIPRISE FINANCIAL INC | 1.2% | 270,262 | +0.13% | 0% | $20,783,148 |
| Sio Capital Management, LLC | 1.2% | 265,543 | +204% | 2.9% | $20,420,257 |
Institutional Holders of ANI PHARMACEUTICALS INC - Common Stock (ANIP) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 23,285,859 | $1,790,008,319 | +$137,327,183 | $76.90 | 275 |
| 2025 Q4 | 21,151,784 | $1,669,959,225 | +$30,069,338 | $78.94 | 284 |
| 2025 Q3 | 20,389,328 | $1,867,651,983 | +$52,854,102 | $91.60 | 266 |
| 2025 Q2 | 19,725,780 | $1,287,090,849 | -$20,870,018 | $65.25 | 229 |
| 2025 Q1 | 19,963,692 | $1,336,584,283 | +$48,405,121 | $66.95 | 226 |
| 2024 Q4 | 19,278,460 | $1,065,666,126 | +$20,364,527 | $55.28 | 204 |
| 2024 Q3 | 18,878,833 | $1,126,182,384 | +$220,571,922 | $59.66 | 207 |
| 2024 Q2 | 15,122,528 | $963,007,127 | +$64,529,569 | $63.68 | 200 |
| 2024 Q1 | 14,090,492 | $974,037,268 | +$37,316,448 | $69.13 | 195 |
| 2023 Q4 | 13,616,342 | $750,788,600 | +$15,033,397 | $55.14 | 180 |
| 2023 Q3 | 13,199,659 | $766,379,240 | +$52,240,515 | $58.06 | 184 |
| 2023 Q2 | 12,299,725 | $662,081,429 | +$105,431,062 | $53.83 | 169 |
| 2023 Q1 | 10,365,411 | $411,702,884 | +$7,764,406 | $39.72 | 137 |
| 2022 Q4 | 10,254,354 | $412,610,775 | +$2,387,720 | $40.23 | 125 |
| 2022 Q3 | 10,269,268 | $330,253,290 | +$12,871,843 | $32.14 | 115 |
| 2022 Q2 | 9,879,095 | $293,397,646 | +$29,894,218 | $29.67 | 109 |
| 2022 Q1 | 9,205,000 | $258,822,043 | -$5,750,270 | $28.11 | 115 |
| 2021 Q4 | 8,972,675 | $413,375,358 | +$78,226,286 | $46.08 | 126 |
| 2021 Q3 | 7,280,546 | $238,830,760 | +$14,353,157 | $32.82 | 105 |
| 2021 Q2 | 7,204,407 | $252,488,638 | -$2,871,513 | $35.05 | 104 |
| 2021 Q1 | 7,293,016 | $263,483,493 | +$391,549 | $36.14 | 100 |
| 2020 Q4 | 7,361,043 | $213,798,867 | +$1,986,104 | $29.04 | 109 |
| 2020 Q3 | 7,312,777 | $206,302,713 | -$6,295,496 | $28.21 | 105 |
| 2020 Q2 | 7,466,801 | $241,329,748 | -$25,517,337 | $32.34 | 124 |
| 2020 Q1 | 7,973,561 | $324,820,687 | -$11,764,194 | $40.74 | 135 |
| 2019 Q4 | 8,093,378 | $499,022,609 | -$70,945,248 | $61.67 | 161 |
| 2019 Q3 | 9,115,689 | $664,230,757 | +$37,860,037 | $72.88 | 181 |
| 2019 Q2 | 8,576,026 | $705,083,478 | +$79,655,054 | $82.20 | 190 |
| 2019 Q1 | 7,702,646 | $543,125,675 | +$45,892,557 | $70.54 | 183 |
| 2018 Q4 | 7,079,477 | $318,725,901 | -$18,340,193 | $45.02 | 158 |
| 2018 Q3 | 7,500,122 | $423,927,111 | +$15,362,009 | $56.54 | 164 |
| 2018 Q2 | 7,191,053 | $480,388,569 | +$39,751,902 | $66.80 | 179 |
| 2018 Q1 | 6,622,638 | $385,621,004 | +$5,056,635 | $58.22 | 166 |
| 2017 Q4 | 6,543,742 | $421,877,087 | +$7,855,697 | $64.45 | 152 |
| 2017 Q3 | 6,413,607 | $336,579,902 | -$1,240,416 | $52.49 | 135 |
| 2017 Q2 | 6,496,859 | $305,032,164 | +$451,131 | $46.80 | 145 |
| 2017 Q1 | 6,453,052 | $319,499,983 | +$59,803,632 | $49.51 | 151 |
| 2016 Q4 | 6,252,710 | $379,236,629 | +$11,513,195 | $60.62 | 151 |
| 2016 Q3 | 6,033,380 | $400,349,646 | +$29,865,427 | $66.35 | 166 |
| 2016 Q2 | 5,605,143 | $312,867,690 | +$11,945,824 | $55.82 | 134 |
| 2016 Q1 | 5,798,068 | $195,120,743 | -$21,503,997 | $33.66 | 115 |
| 2015 Q4 | 6,319,783 | $285,412,733 | -$31,094,929 | $45.12 | 119 |
| 2015 Q3 | 6,966,028 | $275,308,091 | +$16,995,961 | $39.51 | 118 |
| 2015 Q2 | 6,494,641 | $402,533,646 | -$29,199,720 | $62.05 | 120 |
| 2015 Q1 | 6,959,392 | $434,650,108 | +$84,590,578 | $62.55 | 124 |
| 2014 Q4 | 5,627,718 | $317,206,714 | +$97,075,054 | $56.39 | 99 |
| 2014 Q3 | 4,525,202 | $128,520,656 | -$2,966,635 | $28.28 | 69 |
| 2014 Q2 | 4,487,871 | $154,563,359 | +$28,391,675 | $34.44 | 78 |
| 2014 Q1 | 3,764,373 | $118,010,408 | +$77,289,139 | $31.35 | 64 |